Together, we can tackle myopia in children


An estimated 5 billion people, or half the global population, could be affected by myopia by 2050.

Myopia is a global concern.

Annual myopia progression rate is most rapid under 10 years of age. Significantly greater rates of progression can be seen especially in children with high myopia.

If left untreated, myopia can lead to lasting vision problems. But together we can tackle myopia in children.

An innovative spectacle lens.

This spectacle lens based on revolutionary Defocus Incorporated Multiple Segments (D.I.M.S.) Technology was developed in cooperation with The Hong Kong Polytechnic University in 2014. MiYOSMART is easy to fit, just like regular single vision lens. There are no limitations for the frame choice.


In 2018, the MiYOSMART lens won the Gold Prize, Grand Award & Special Gold Award International Exhibition of Inventions of Geneva, Switzerland. In 2020, it won the Silmo d’Or Award in the Vision category at the Silmo Paris Optical Fair.

A revolutionary technology.

With the exclusive non-invasive D.I.M.S. Technology, the lens corrects the visual defect on its entire surface and has a ring shaped treatment area to slow down myopia progression. The alternation of the focus area and defocus area provides clear vision and manages myopia simultaneously.

Scientific Evidence of MiYOSMART

2-year Randomized Clinical Trial

Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial (BJO)

Read the full study

3-year Follow-up Study

Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study (BJO)

Read the full study

6-year Follow-up Study

Myopia control in children wearing DIMS spectacle lens: 6 years results (Abstract ARVO 2022)

Download the abstract
Image of children wearing classes within a classroom

Designed to fit a child’s active life.

MiYOSMART comes with an easy-to-wipe special anti-reflective, durable coating. With its Eye Shield, young patients get the added assurance of an impact resistant material and UV protection.

Image of children wearing classes within a classroom

The Latest News from MiYOSMART

See all the news
Keeping in the know

HOYA Vision Care Supports The World Society of Paediatric Ophthalmology and Strabismus to Address the Growing Issue of Myopia

Read the full story

HOYA Vision Care Brings Together Key Experts to Further Improve Myopia Management

Read the full story

HOYA Vision Care Presents Results of First Six-Year MiYOSMART Spectacle Lens Follow-up Clinical Study at EAOO Conference

Read the full story

HOYA Vision Care and International Myopia Institute Launch Partnership

Read the full story

*PRODUCT DISCLAIMER – MiYOSMART has not been approved for myopia management in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S.

1. Brien Holden Vision Institute; 2 Shanghai Eye Disease Prevention and Treatment Center, accessed 16.08.1018.

2. Lam CSY, Tang WC, Lee RPK, Chun RKM, To CH. A randomized clinical trial for myopia control – use of myopic defocus spectacle lens. 8th International Congress of Behavioral Optometry (ICBO), 26- 29 of April 2018. Sydney, Australia. 8Sankaridurg P1, Tilia D1, Morton M1, Weng R1, Jong M1, Zhu F2. Guidelines for Myopia Management.